Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

作者: P. E. Makidon , J. Knowlton , J. V. Groom , L. P. Blanco , J. J. LiPuma

DOI: 10.1007/S00430-009-0137-2

关键词:

摘要: Burkholderia cepacia complex (Bcc) are opportunistic bacteria associated with life-threatening illness in persons cystic fibrosis. Once Bcc colonization is established, these antimicrobial-resistant and biofilm-forming difficult to eradicate increased rates of morbidity mortality. At present, no vaccines available prevent the infection. There currently a paucity published information regarding development designed colonization. This work expands on recent studies by Bertot et al. [Infect Immun 75(6):2740–2752, 2007], where successful protective immune responses were generated mice using B. multivorans OMP-based vaccine. Here, we evaluate an experimental mucosal vaccine against novel adjuvant (nanoemulsion) cenocepacia-based OMP antigen. The antigen derived from cenocepacia was mixed either nanoemulsion or PBS delivered intranasally CD-1 mice. Serum analysis showed robust IgG secretory IgA vaccinated versus control antibodies had cross-neutralizing activity both species. We found that immunized protected pulmonary cenocepacia. have also identified 17 kDa OmpA-like protein highly conserved between Ralstonia species as new immunodominant epitope immunization.

参考文章(38)
Tom Coenye, Peter Vandamme, Burkholderia : molecular microbiology and genomics Horizon Bioscience. ,(2007)
Pascale Jeannin, Toufic Renno, Liliane Goetsch, Isabelle Miconnet, Jean-Pierre Aubry, Yves Delneste, Nathalie Herbault, Thierry Baussant, Giovanni Magistrelli, Caroline Soulas, Pedro Romero, Jean-Charles Cerottini, Jean-Yves Bonnefoy, OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nature Immunology. ,vol. 1, pp. 502- 509 ,(2000) , 10.1038/82751
Leo Eberl, Burkhard Tümmler, Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis: genome evolution, interactions and adaptation. International Journal of Medical Microbiology. ,vol. 294, pp. 123- 131 ,(2004) , 10.1016/J.IJMM.2004.06.022
T. Hamouda, J.R. Baker, Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. Journal of Applied Microbiology. ,vol. 89, pp. 397- 403 ,(2000) , 10.1046/J.1365-2672.2000.01127.X
John J. LiPuma, Sivaprakash Rathinavelu, Bridget K. Foster, Jordan C. Keoleian, Paul E. Makidon, Linda M. Kalikin, James R. Baker, In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species Antimicrobial Agents and Chemotherapy. ,vol. 53, pp. 249- 255 ,(2009) , 10.1128/AAC.00691-08
A.G. Al-Bakri, P. Gilbert, D.G. Allison, Immigration and emigration of Burkholderia cepacia and Pseudomonas aeruginosa between and within mixed biofilm communities. Journal of Applied Microbiology. ,vol. 96, pp. 455- 463 ,(2004) , 10.1111/J.1365-2672.2004.02201.X
Kerry L. Tomlin, Scott R.D. Clark, Howard Ceri, Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. Journal of Microbiological Methods. ,vol. 57, pp. 95- 106 ,(2004) , 10.1016/J.MIMET.2003.12.007
M M Brett, A T Ghoneim, J M Littlewood, Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection. Archives of Disease in Childhood. ,vol. 62, pp. 357- 361 ,(1987) , 10.1136/ADC.62.4.357
Anna U. Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, David M. Markovitz, David C. Montefiori, James R. Baker, Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Research and Human Retroviruses. ,vol. 24, pp. 271- 281 ,(2008) , 10.1089/AID.2007.0148